# Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

> **NCT02461719** · PHASE3 · COMPLETED · sponsor: **Taejoon Pharmaceutical Co., Ltd.** · enrollment: 158 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** CYPORIN N EYE DROPS 0.05%(TJCS eye drop)
- **DRUG:** Restasis

## Key facts

- **NCT ID:** NCT02461719
- **Lead sponsor:** Taejoon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2015-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461719, "Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02461719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*